These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

837 related articles for article (PubMed ID: 25679794)

  • 1. LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): design, synthesis and biochemical evaluation.
    Alghamdi RH; O'Reilly P; Lu C; Gomes J; Lagace TA; Basak A
    Eur J Med Chem; 2015 Mar; 92():890-907. PubMed ID: 25679794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory effects of peptides from the pro and catalytic domains of proprotein convertase subtilisin/kexin 9 (PCSK9) on low-density lipoprotein receptor (LDL-R).
    Palmer-Smith H; Basak A
    Curr Med Chem; 2010; 17(20):2168-82. PubMed ID: 20423303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterisation of de novo mutations in the C-terminal domain of proprotein convertase subtilisin/kexin type 9.
    Geschwindner S; Andersson GM; Beisel HG; Breuer S; Hallberg C; Kihlberg BM; Lindqvist AM; O'Mahony G; Plowright AT; Raubacher F; Knecht W
    Protein Eng Des Sel; 2015 May; 28(5):117-25. PubMed ID: 25744035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of truncated EGF-A peptides that restore LDL-R recycling in the presence of PCSK9 in vitro.
    Schroeder CI; Swedberg JE; Withka JM; Rosengren KJ; Akcan M; Clayton DJ; Daly NL; Cheneval O; Borzilleri KA; Griffor M; Stock I; Colless B; Walsh P; Sunderland P; Reyes A; Dullea R; Ammirati M; Liu S; McClure KF; Tu M; Bhattacharya SK; Liras S; Price DA; Craik DJ
    Chem Biol; 2014 Feb; 21(2):284-94. PubMed ID: 24440079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
    Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
    Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo.
    Schiele F; Park J; Redemann N; Luippold G; Nar H
    J Mol Biol; 2014 Feb; 426(4):843-52. PubMed ID: 24252255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels.
    Lipari MT; Li W; Moran P; Kong-Beltran M; Sai T; Lai J; Lin SJ; Kolumam G; Zavala-Solorio J; Izrael-Tomasevic A; Arnott D; Wang J; Peterson AS; Kirchhofer D
    J Biol Chem; 2012 Dec; 287(52):43482-91. PubMed ID: 23135270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor.
    Zhang Y; Eigenbrot C; Zhou L; Shia S; Li W; Quan C; Tom J; Moran P; Di Lello P; Skelton NJ; Kong-Beltran M; Peterson A; Kirchhofer D
    J Biol Chem; 2014 Jan; 289(2):942-55. PubMed ID: 24225950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding to the low-density lipoprotein receptor accelerates futile catalytic cycling in PCSK9 and raises the equilibrium level of intramolecular acylenzyme.
    Geoghegan KF; Hoth LR; Varghese AH; Lin W; Boyd JG; Griffor MC
    Biochemistry; 2009 Apr; 48(13):2941-9. PubMed ID: 19222187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels.
    Marais AD; Kim JB; Wasserman SM; Lambert G
    Pharmacol Ther; 2015 Jan; 145():58-66. PubMed ID: 25046268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico Screening of Chemical Libraries to Develop Inhibitors That Hamper the Interaction of PCSK9 with the LDL Receptor.
    Min DK; Lee HS; Lee N; Lee CJ; Song HJ; Yang GE; Yoon D; Park SW
    Yonsei Med J; 2015 Sep; 56(5):1251-7. PubMed ID: 26256967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PCSK9 inhibitors: the next frontier in low-density lipoprotein lowering.
    Jialal I; Patel SB
    Metab Syndr Relat Disord; 2015 Apr; 13(3):99-101. PubMed ID: 25734961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering.
    Mitchell T; Chao G; Sitkoff D; Lo F; Monshizadegan H; Meyers D; Low S; Russo K; DiBella R; Denhez F; Gao M; Myers J; Duke G; Witmer M; Miao B; Ho SP; Khan J; Parker RA
    J Pharmacol Exp Ther; 2014 Aug; 350(2):412-24. PubMed ID: 24917546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PCSK9: a key modulator of cardiovascular health.
    Seidah NG; Awan Z; Chrétien M; Mbikay M
    Circ Res; 2014 Mar; 114(6):1022-36. PubMed ID: 24625727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide.
    Shan L; Pang L; Zhang R; Murgolo NJ; Lan H; Hedrick JA
    Biochem Biophys Res Commun; 2008 Oct; 375(1):69-73. PubMed ID: 18675252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A semi-automated mass spectrometric immunoassay coupled to selected reaction monitoring (MSIA-SRM) reveals novel relationships between circulating PCSK9 and metabolic phenotypes in patient cohorts.
    Gauthier MS; Pérusse JR; Awan Z; Bouchard A; Tessier S; Champagne J; Krastins B; Byram G; Chabot K; Garneau P; Rabasa-Lhoret R; Faubert D; Lopez MF; Seidah NG; Coulombe B
    Methods; 2015 Jun; 81():66-73. PubMed ID: 25770357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.
    Tavori H; Fan D; Blakemore JL; Yancey PG; Ding L; Linton MF; Fazio S
    Circulation; 2013 Jun; 127(24):2403-13. PubMed ID: 23690465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New hypotheses about the structure-function of proprotein convertase subtilisin/kexin type 9: analysis of the epidermal growth factor-like repeat A docking site using WaterMap.
    Pearlstein RA; Hu QY; Zhou J; Yowe D; Levell J; Dale B; Kaushik VK; Daniels D; Hanrahan S; Sherman W; Abel R
    Proteins; 2010 Sep; 78(12):2571-86. PubMed ID: 20589640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.